David Ricks, Eli Lilly CEO (Evan Vucci/AP Images)

Eli Lil­ly un­veils a com­plete makeover, erect­ing a neu­ro­science unit cen­tered on Alzheimer's as it uni­fies on­col­o­gy biz

The FDA ap­proval of Bio­gen’s Aduhelm for Alzheimer’s has breathed new life in­to neu­rol­o­gy units across bio­phar­ma, none more so than near­est ri­val Eli Lil­ly. Look­ing to ride that build­ing wave, Lil­ly is ready for a new look.

Lil­ly will break up its larg­er Bio-Med­i­cines busi­ness, prop­ping up new neu­ro­science and im­munol­o­gy units as part of a broad re­or­ga­ni­za­tion of the In­di­anapo­lis drug­mak­er’s pipeline cen­tered, in part, around late-stage Alzheimer’s can­di­date do­nanemab, the com­pa­ny an­nounced Tues­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.